Lisata Therapeutics to be Taken Private by Kuva Labs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy ATRA?
Source: Benzinga
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.930
Low
18.00
Averages
21.50
High
25.00
Current: 9.930
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atara Biotherapeutics Shares Surge 43% on FDA Update
- FDA Progress: Atara's Tabelecleucel, developed with Pierre Fabre, received a positive signal from the FDA indicating that a single-arm study with a historical control could support a future marketing application, suggesting a potential path forward for the company.
- Stock Price Surge: Shares of Atara Biotherapeutics (ATRA) surged over 43% in morning trading on Thursday, marking the largest single-day gain in more than two years, reflecting strong market optimism following the FDA update, which may enhance investor confidence.
- Initial Application Rejection: The FDA previously rejected Atara's initial application in January 2026, citing concerns over trial design and analysis; however, Atara has since submitted updated long-term efficacy data to support a resubmission, demonstrating the company's commitment to addressing regulatory challenges.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from neutral to 'extremely bullish', yet some users expressed skepticism about the sustainability of the rally, indicating a complex market perception regarding Atara's future performance.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors about a class action lawsuit against Atara Biotherapeutics for violations of securities laws, concerning trades from May 20, 2024, to January 9, 2026, with a deadline to contact the firm by May 22, 2026, for participation.
- False Statement Allegations: The complaint alleges that Atara made false and misleading statements regarding its product tabelecleucel, resulting in investor losses when the truth emerged, indicating the company faced heightened regulatory risks.
- Manufacturing Issues Impact: Atara's manufacturing problems in its ALLELE study have diminished the likelihood of FDA approval for its Biologics License Application, further exacerbating investor risks and potential losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to supporting investor interests.
See More
Atara Biotherapeutics (ATRA.US) 10% Stakeholder Plans to Sell 3.17 Million Shares via Form 144
Stockholder Sale Announcement: Atara Biotherapeutics' 10% stockholder, Panacea Innovation Ltd, plans to sell 313,450 shares of its common stock on May 7.
Market Value: The total market value of the shares being sold is approximately $3.17 million.
See More
Atara Biotherapeutics Shares Surge Nearly 100% Following FDA Meeting
- Positive FDA Meeting: Atara Biotherapeutics clarified the regulatory pathway for its cell therapy candidate tabelecleucel during a meeting with the FDA, which indicated that a single-arm study using relevant historical controls could suffice for a future Biologics License Application, providing new hope for the company.
- Strong Market Reaction: Following the meeting, Atara's stock surged nearly 100%, reflecting investor optimism regarding the FDA's change in stance, which significantly enhances market recognition of the potential of this treatment option.
- Robust Financial Performance: Atara reported a GAAP EPS of $2.61, exceeding expectations by $4.06, with revenue reaching $120.8 million, indicating strong financial performance that bolsters market confidence in its future growth prospects.
- Ongoing Strategic Collaboration: CEO Cokey Nguyen stated that Atara will continue to support its partner Pierre Fabre Pharmaceuticals in preparing for the resubmission and anticipates providing further regulatory updates in the third quarter, demonstrating the company's commitment to advancing its treatment options.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics faces a class action lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that overstated FDA approval prospects, potentially leading to significant negative impacts on the company's financial condition.
- Coty Performance Decline: Coty Inc. is under scrutiny in a class action lawsuit covering November 5, 2025, to February 4, 2026, with claims that its Consumer Beauty segment underperformed, increased marketing investments compressed margins, and slowing growth in the Prestige fragrance market rendered the company's positive statements misleading.
- Super Micro Sales Violations: Super Micro Computer is implicated in a class action lawsuit for the period from February 2, 2024, to March 19, 2026, alleging that a significant portion of its server sales to Chinese companies violated U.S. export control laws, with material weaknesses in compliance controls leading to misleading positive statements about the company's operations.
- ImmunityBio Capability Overstatement: ImmunityBio faces a class action lawsuit for the period from January 19, 2026, to March 24, 2026, alleging that executive Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading positive statements about the company's business and operations, which could undermine investor confidence.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Atara Biotherapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegations: The complaint claims that the defendants failed to disclose manufacturing issues and deficiencies in the ALLELE study, making FDA approval of the tabelecleucel BLA unlikely, thereby overstating its regulatory prospects and increasing the risk of regulatory scrutiny.
- Business Impact: These issues are likely to have a significant negative impact on Atara's business and financial condition, undermining investor confidence and potentially leading to a decline in stock price.
- Investor Action: Affected investors have until May 22, 2026, to request to be appointed as lead plaintiff, with Bronstein, Gewirtz & Grossman, LLC representing investors on a contingency fee basis, only charging if successful.
See More
Atara Biotherapeutics Shares Surge 43% on FDA Update
- FDA Progress: Atara's Tabelecleucel, developed with Pierre Fabre, received a positive signal from the FDA indicating that a single-arm study with a historical control could support a future marketing application, suggesting a potential path forward for the company.
- Stock Price Surge: Shares of Atara Biotherapeutics (ATRA) surged over 43% in morning trading on Thursday, marking the largest single-day gain in more than two years, reflecting strong market optimism following the FDA update, which may enhance investor confidence.
- Initial Application Rejection: The FDA previously rejected Atara's initial application in January 2026, citing concerns over trial design and analysis; however, Atara has since submitted updated long-term efficacy data to support a resubmission, demonstrating the company's commitment to addressing regulatory challenges.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from neutral to 'extremely bullish', yet some users expressed skepticism about the sustainability of the rally, indicating a complex market perception regarding Atara's future performance.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors about a class action lawsuit against Atara Biotherapeutics for violations of securities laws, concerning trades from May 20, 2024, to January 9, 2026, with a deadline to contact the firm by May 22, 2026, for participation.
- False Statement Allegations: The complaint alleges that Atara made false and misleading statements regarding its product tabelecleucel, resulting in investor losses when the truth emerged, indicating the company faced heightened regulatory risks.
- Manufacturing Issues Impact: Atara's manufacturing problems in its ALLELE study have diminished the likelihood of FDA approval for its Biologics License Application, further exacerbating investor risks and potential losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to supporting investor interests.
See More
Atara Biotherapeutics (ATRA.US) 10% Stakeholder Plans to Sell 3.17 Million Shares via Form 144
Stockholder Sale Announcement: Atara Biotherapeutics' 10% stockholder, Panacea Innovation Ltd, plans to sell 313,450 shares of its common stock on May 7.
Market Value: The total market value of the shares being sold is approximately $3.17 million.
See More
Atara Biotherapeutics Shares Surge Nearly 100% Following FDA Meeting
- Positive FDA Meeting: Atara Biotherapeutics clarified the regulatory pathway for its cell therapy candidate tabelecleucel during a meeting with the FDA, which indicated that a single-arm study using relevant historical controls could suffice for a future Biologics License Application, providing new hope for the company.
- Strong Market Reaction: Following the meeting, Atara's stock surged nearly 100%, reflecting investor optimism regarding the FDA's change in stance, which significantly enhances market recognition of the potential of this treatment option.
- Robust Financial Performance: Atara reported a GAAP EPS of $2.61, exceeding expectations by $4.06, with revenue reaching $120.8 million, indicating strong financial performance that bolsters market confidence in its future growth prospects.
- Ongoing Strategic Collaboration: CEO Cokey Nguyen stated that Atara will continue to support its partner Pierre Fabre Pharmaceuticals in preparing for the resubmission and anticipates providing further regulatory updates in the third quarter, demonstrating the company's commitment to advancing its treatment options.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics faces a class action lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that overstated FDA approval prospects, potentially leading to significant negative impacts on the company's financial condition.
- Coty Performance Decline: Coty Inc. is under scrutiny in a class action lawsuit covering November 5, 2025, to February 4, 2026, with claims that its Consumer Beauty segment underperformed, increased marketing investments compressed margins, and slowing growth in the Prestige fragrance market rendered the company's positive statements misleading.
- Super Micro Sales Violations: Super Micro Computer is implicated in a class action lawsuit for the period from February 2, 2024, to March 19, 2026, alleging that a significant portion of its server sales to Chinese companies violated U.S. export control laws, with material weaknesses in compliance controls leading to misleading positive statements about the company's operations.
- ImmunityBio Capability Overstatement: ImmunityBio faces a class action lawsuit for the period from January 19, 2026, to March 24, 2026, alleging that executive Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading positive statements about the company's business and operations, which could undermine investor confidence.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Atara Biotherapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegations: The complaint claims that the defendants failed to disclose manufacturing issues and deficiencies in the ALLELE study, making FDA approval of the tabelecleucel BLA unlikely, thereby overstating its regulatory prospects and increasing the risk of regulatory scrutiny.
- Business Impact: These issues are likely to have a significant negative impact on Atara's business and financial condition, undermining investor confidence and potentially leading to a decline in stock price.
- Investor Action: Affected investors have until May 22, 2026, to request to be appointed as lead plaintiff, with Bronstein, Gewirtz & Grossman, LLC representing investors on a contingency fee basis, only charging if successful.
See More
